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Objectives This study was designed to determine the prognostic value of multidetector coronary computed tomography an-
giography (CTA) in relation to exercise electrocardiography (XECG) findings.
Background The prognostic usefulness of coronary CTA findings of coronary artery disease in relation to XECG findings has
not been explored systematically.
Methods Patients with suspected coronary artery disease who had undergone both coronary CTA and XECG (90 days
between tests) from 2003 through 2009 were enrolled retrospectively. Coronary CTA results were classified ac-
cording to the severity of maximal stenosis (normal, mild: 40% of luminal stenosis, moderate: 40% to 69%,
severe: 70%), XECG results were categorized as positive and negative, and Duke XECG score was calculated.
Clinical follow-up data were collected for major adverse cardiac events (MACE): cardiac death, nonfatal myocar-
dial infarction, unstable angina requiring hospitalization, and revascularization after 90 days from index coronary
CTA. C-statistics were calculated to compare discriminatory values of each test.
Results Among the 2,977 (58  10 years) study patients, 12% demonstrated positive XECG results. By coronary CTA,
patients were categorized as normal (56%) or having mild (26%), moderate (13%), or severe (5%) disease. Dur-
ing a median follow-up of 3.3 years (interquartile range: 2.3 to 4.6), 97 MACE were observed and the 5-year cu-
mulative event rate was 3.6% (95% confidence interval: 3.0 to 4.3). Although both XECG (C-statistic: 0.790) and
coronary CTA (C-statistic: 0.908) improved risk stratification beyond clinical risk factors (C-statistic: 0.746, p 
0.05 for all), XECG in addition to coronary CTA (C-statistic: 0.907) did not provide better discrimination than coro-
nary CTA alone (p  0.389). In subgroup analyses, coronary CTA stratified risk of MACE in groups with both posi-
tive and negative XECG results (all p  0.001 for trend). However, positive XECG results predicted risk of MACE
on coronary CTA only in the moderate stenosis group (hazard ratio: 2.58, 95% confidence interval: 1.29 to 5.19,
p  0.008) and severe stenosis group (hazard ratio: 2.28, 95% confidence interval: 1.19 to 4.38, p  0.013).
Conclusions In patients with suspected coronary artery disease, coronary CTA discriminates future risk of MACE in patients
independent of XECG results. Compared with coronary CTA, XECG has an additive prognostic value only in pa-
tients with moderate to severe stenosis on coronary CTA. (J Am Coll Cardiol 2012;60:2205–15) © 2012 by the
American College of Cardiology Foundation
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(XECG) has been a widely used
test in diagnosing and prognos-
ticating individuals with sus-
pected coronary artery disease
(CAD) (1–3). Current guidelines
recommend XECG as the first
diagnostic step of suspected
CAD in patients who are able to
exercise (1). However, its useful-
ness is limited by a modest sen-
sitivity and specificity of 68% and
77%, respectively, across a wide
range of patient subsets (2).
See page 2216
Recently, coronary computed
tomography angiography (CTA)
was introduced as a novel, noninvasive approach for the
evaluation of CAD. Because coronary CTA demonstrates
high specificity and negative predictive value in the exclu-
sion of CAD (3–5), it has been suggested as a potential
noninvasive method to rule in or rule out obstructive CAD.
Although previous studies revealed the superior diagnostic
accuracy of coronary CTA compared with XECG (6,7), to
date, the prognostic value of coronary CTA has not been
compared adequately with that of stress tests (8,9). In
addition, the usefulness of coronary CTA as an alternative
or an adjunct to stress tests (including XECG) in the
diagnostic work-up as well as risk stratification of patients
with chest pain remains to be studied. Because the value of
any noninvasive diagnostic strategy is determined in large
part by its prognostic benefit, we thus sought to assess the
prognostic value of coronary CTA in relation to XECG in
patients with suspected CAD.
Methods
Design overview, setting, and participants. The initial
study sample included 3,944 consecutive patients who had
undergone both coronary CTA and XECG within 90 days
for evaluation of suspected CAD at Severance Cardiovas-
cular Hospital from May 2003 through April 2009 without
any other cardiovascular testing. Patients were excluded who
1) were younger than 30 years (n  63); 2) had a history of
prior myocardial infarction (MI), coronary revasculariza-
tion, or cardiac transplantation (n  21); 3) had inadequate
XECG (137 patients); 4) had insufficient medical records
or uninterpretable coronary CTA results (n  26); and 5)
were without at least 1 of following symptoms or signs:
angina, angina equivalent symptoms, or abnormal resting
electrocardiography (ECG) results (n  720). After exclu-
sion according to the study criteria, a total of 2,977 patients
remained for final analysis. The median number of days
Abbreviations
and Acronyms
CAD  coronary artery
disease
CI  confidence interval
CT  computed
tomography
CTA  computed
tomography angiography
ECG  electrocardiography
HR  hazard ratio
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
RF  risk factor
XECG  exercise
electrocardiographybetween coronary CTA and XECG was 8 days (interquar-tile range: 2 to 14 days). Clinical indications of coronary
CTA and XECG are listed in Online Table 1. Pretest
likelihood of CAD was determined based on American
College of Cardiology/American Heart Association guide-
lines, which were modified from the literature review of
Diamond and Forrester (10,11) (Online Table 2).
Clinical data were collected at the time of the index visit.
Hypertension was defined by current use of antihypertensive
medications or a blood pressure of 140/90 mm Hg or more.
Diabetes mellitus was defined as receiving antidiabetic
treatments or a fasting plasma glucose of 126 mg/dl or
more. Current cigarette smoking was defined as any ciga-
rette smoking in the past month. Dyslipidemia was
defined as use of cholesterol-lowering medications or
having a total serum cholesterol of 200 mg/dl or more.
Institutional review committee approval and informed
consent were obtained.
Coronary CTA protocol and image analysis. Data acqui-
sition and image analysis were carried out as described
previously (12). Briefly, patients without a contraindication
to beta-adrenergic blocking agents (bronchial asthma, overt
heart failure, and atrioventricular conduction abnormalities)
and with initial heart rates higher than 65 beats/min
received a single oral dose of 40 mg propranolol hydrochlo-
ride (Pranol; Dae Woong, Seoul, Korea) 1 h before coronary
CTA. The patients’ mean heart rate during the CT exam-
ination was 58  7 beats/min (range: 34 to 110 beats/min).
Two types of CT system configurations were used: 1) a
64-slice CT scanner (Sensation 64, Siemens Medical Solu-
tions, Forchheim, Germany) using retrospective ECG gat-
ing with tube current modulation from 2003 through 2009
with the following parameters: rotation time: 330 ms, tube
voltage: 100 to 120 KeV, tube current: 400 to 800 mA, and
pitch factor: 0.2; and 2) a 64-row CT scanner (LightSpeed
VCT XT, GE Healthcare, Milwaukee, Wisconsin) using
prospectively an ECG-gated axial technique from 2008
through 2009 with the following parameters: rotation time:
350 ms, tube voltage: 100 to 120 KeV, and tube current: 300
to 900 mA. A real-time bolus-tracking technique was
applied to trigger the initiation of the scan. Contrast
enhancement was achieved with 75 ml iopamidol (370 mg
iodine per milliliter, Iopamiro, Bracco, Milan, Italy) in-
jected at 5 ml/s, followed by an injection of 50 ml of saline
at 5 ml/s by using a power injector (Envision CT, Medrad,
Indianola, Pennsylvania) via an antecubital vein.
Image reconstruction was performed on the scanner’s
workstation using commercially available software (Wizard,
Siemens Medical Solutions, or GEAW, GE healthcare).
Axial images were reconstructed retrospectively at 65% of
the RR interval for each cardiac cycle. If artifacts appeared,
additional data sets were obtained for various points of the
cardiac cycle, and the data set with the minimum artifact
was selected for further analysis. The reconstructed image
data sets were transferred to an off-line workstation (Aquar-
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for postprocessing and analysis. Each lesion identified was
examined using maximum intensity projection and multi-
planar reconstruction techniques on a short axis and along
multiple longitudinal axes. Lesions were classified by the
maximal luminal diameter stenosis seen on any plane.
Coronary CTA was evaluated by 2 experienced cardiac
radiologists (Y.J.K. and B.W.C., with 6 and 9 years expe-
rience in coronary CTA, respectively), who were blinded to
XECG results of each patient. In case of disagreement, a
joint reading was performed to reach a consensus.
We used 3 different coronary CTA models to compare
with prognostic values of XECG: 1) a binary obstructive
CAD model; 2) an extent of CAD model; and 3) a severity
of CAD model. Obstructive CAD was defined when
coronary artery segments exhibited plaque with a luminal
diameter stenosis of 50% or more. Extent of CAD was
classified as the number of obstructive vessels (50%): no
obstructive CAD (absence of obstructive CAD), 1-vessel
disease (VD), 2-VD, and 3-VD. In addition, severity of
CAD was classified into 4 categories according the degree of
stenosis (13): normal (absence of CAD), mild (1% to 39%
luminal narrowing in DS), moderate (40% to 69% luminal
narrowing in DS); and severe (70% luminal narrowing in
DS) stenosis.
XECG protocol. A symptom-limited exercise treadmill
test was performed according to the Bruce protocol (14).
During exercise stress test, heart rhythm and blood pressure
were recorded at rest, at the end of each stage of exercise, at
peak stress, and during recovery. A 12-lead ECG was
obtained every minute, and a 3-lead ECG for heart rhythm
was monitored continuously. Indications for terminating
the exercise test were as previously described (11). In the
summary of the XECG data set (summary XECG), results
of the stress test were classified as positive when the ST
segment appeared horizontal or had a down-sloping depres-
sion of 1 mm or more for 60 to 80 ms after the end of the QRS
complex (11). Inadequate stress tests of patients who had not
reached the reference standards established for age, sex, and
weight were excluded from the analysis. The detailed methods
to record XECG parameters and to calculate Duke treadmill
score are described in the Online Methods.
Follow-up. Clinical follow-up data were obtained via re-
view of electronic medical records and telephone contact by
a dedicated physician, research nurse, or both, who were
blinded to coronary CTA and XECG results. The primary
endpoint was the occurrence of major adverse cardiac events
(MACE), defined as cardiac death, nonfatal MI, unstable
angina requiring hospitalization, and revascularization ei-
ther by percutaneous coronary intervention or coronary
artery bypass graft after 90 days of the index test. Coronary
revascularizations occurring within 90 days after the index
test were not included in the analyses to exclude any
test-driven procedure from being considered as a MACE
(15–17). wStatistical analysis. Discrete variables were presented as
numbers (percentages), and continuous variables were ex-
pressed as mean  SD or median with interquartile range,
as appropriate. Differences between continuous variables
were analyzed by analysis of variance tests, and those
between categorical variables were analyzed by the chi-
square test or Fisher exact test, as appropriate. Cumulative
event rates as a function of time were calculated using
Kaplan-Meier survival analysis for XECG results and
coronary CTA-diagnosed CAD and were compared us-
ing the log-rank statistic. Five-year estimated incident
MACE risk was calculated for each participant using Cox
proportional hazards model. Univariate and multivariate
models were calculated to identify XECG and coronary
CTA predictors of outcome. From the Cox hazard
models, hazard ratios (HRs) and 95% confidence inter-
vals (CIs) were calculated.
To evaluate the discriminatory function of each model,
C-statistics for the following models were calculated
(18,19): model 1, clinical risk factors (RF); model 2, RF 
summary XECG; model 3, RF summary XECGDuke
treadmill test score; model 4, RF  coronary CTA; model
, RF  summary XECG  coronary CTA; model 6,
F  summary XECG  Duke treadmill test score 
oronary CTA. p Values less than 0.05 were considered to
e statistically significant. Statistical analysis was performed
sing SAS software version 9.2 (SAS Institute Inc., Cary,
orth Carolina) and R software version 2.13.1.
esults
linical characteristics of study population. Overall, the
tudy population consisted of 2,977 patients. The mean age
f patients was 58  10 years and 50% were male. The
revalences of clinical RF were as follows: diabetes, 16%;
ypertension, 48%; dyslipidemia, 44%; and current smok-
ng, 13%. In subset groups of the more severe CAD,
atients were male, older, diabetic, and hypertensive (all p
.001) (Table 1). More than one-half of the study popula-
ion (1,825 patients, 61%) had intermediate pretest proba-
ility of CAD, and 823 (28%) had low pretest probability of
AD. Ninety patients (3%) had high pretest probability of
AD. Detailed patient characteristics are summarized in
able 1.
ECG and coronary CTA results. As demonstrated in
able 2, 358 (12%) patients had positive XECG results, and
30 (4%) had equivocal XECG results among study cohort.
y coronary CTA, 409 (13%) patients had obstructive
AD: 1-VD (274, 9%), 2-VD (92, 3%), or 3-VD (43, 1%).
n terms of severity of CAD, patients were classified as
aving mild (782, 26%), moderate (372, 13%), and severe
155, 5%) CAD.
Prevalence of obstructive CAD (1-, 2-, or 3-VD) in
atients with positive XECG results was higher than those
ith negative XECG results (28% vs. 11%, respectively, p
tes me
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severe (16%) CAD was higher in patients with positive
XECG results than in those with negative XECG results
(11% and 7% respectively, all p  0.001).
Clinical outcomes. During a median follow-up of 3.34
years (interquartile range: 2.33 to 4.55), a total of 97
MACE were observed. These included 3 cardiac deaths, 6
nonfatal MI (4 ST-segment elevation MI and 2 non–ST-
segment elevation MI), 8 cases of unstable angina requiring
hospitalization, and 80 revascularizations after 90 days from
the index test (Table 3). The overall 5-year cumulative event
rate was 3.6% (95% CI: 3.0 to 4.3). Patients without
obstructive CAD (no CAD or nonobstructive CAD) on
coronary CTA experienced 22 MACE during the follow-up
period, and the 5-year MACE rate was 0.9% (95% CI: 0.6%
to 1.4%). In particular, only 2 MACE (2 nonfatal MI) were
Baseline Characteristics According to the Severity of CAD EvidencTable 1 Baseline Characteristics According to the Severity of C
Variables
Overall
(n  2,977) Normal (n  1,668)
Male 1,476 (50%) 702 (42%)
Age, yrs 58 10 55 9
DM 455 (16%) 164 (10%)
Hypertension 1,413 (48%) 685 (41%)
Dyslipidemia 1,300 (44%) 736 (44%)
Current smoking 397 (13%) 223 (13%)
TC 186 36 187 34
LDL-C 119 34 120 32
HDL-C 51 12 52 13
FBS 102 25 98 20
Pretest probability of CAD
Very low (5%) 239 (8%) 195 (12%)
Low (6%–9%) 823 (28%) 497 (30%)
Intermediate (10%–90%) 1,825 (61%) 948 (57%)
High (90%) 90 (3%) 28 (2%)
Values are n (%) or mean  SD. *CAD severity by coronary CTA was classified according to the sev
moderate (40% to 69%), and severe ( 70%).
CAD coronary artery disease; coronary CTA computed tomography angiography; DM diabe
lipoprotein cholesterol; NA  not applicable; TC  total cholesterol.
Results of Coronary CTA in Relation to SummarTable 2 Results of Coronary CTA in Relation
Variables
Overall
(n  2,977)
Extent of CAD
No obstructive CAD 2,568 (86%)
Obstructive 1-VD 274 (9%)
Obstructive 2-VD 92 (3%)
Obstructive 3-VD 43 (1%)
Severity of CAD†
Normal 1,668 (56%)
Mild stenosis (1%–39%) 782 (26%)
Moderate stenosis (40%–69%) 372 (13%)
Severe stenosis (70%) 155 (5%)
*Percentage of patients in each XECG subset. †Severity of CAD was ca
narrowing in diameter stenosis).
VD  vessel disease; XECG  exercise electrocardiogram; other abbreviatireported in patients without CAD (no stenosis) on coronary
CTA during follow-up (5-year cumulative event rate: 0.1%,
95% CI: 0.03 to 0.50). These nonfatal MI occurred as a
result of severe coronary spasm confirmed by invasive
coronary angiogram and of essential thrombocytosis in the
absence of epicardial obstructive CAD. However, 54
MACE were observed in patients with negative XECG
results (5-year cumulative event rate: 2.4%, 95% CI: 1.8 to
3.1). Detailed MACE according to study results are sum-
marized in Table 3. In addition, a detailed description of
revascularization procedures in relation to index coronary
CTA findings are listed in Online Table 3. Most revascu-
larization procedures (85%, 79 cases) targeted coronary
lesions that had been detected by index coronary CTA: 63%
had been obstructive ( 50%) and 22% were nonobstructive
on index coronary CTA.
Coronary CTAEvidenced by Coronary CTA
CAD Severity* by Coronary CTA
p Value(n  782) Moderate (n  372) Severe (n  155)
2 (55%) 236 (63%) 106 (68%) 0.0001
1 8 62 8 63 8 0.0001
3 (20%) 96 (26%) 42 (28%) 0.0001
5 (54%) 216 (60%) 97 (63%) 0.0001
8 (42%) 165 (45%) 71 (46%) 0.914
3 (12%) 55 (15%) 26 (17%) 0.369
6 38 186 38 189 41 0.777
8 35 117 36 121 41 0.592
1 11 48 11 47 12 0.0001
6 30 108 28 110 29 0.0001
0.0001
2 (4%) 9 (2%) 3 (2%)
3 (23%) 112 (30%) 31 (20%)
8 (70%) 238 (64%) 91 (59%)
9 (2%) 13 (4%) 30 (19%)
maximal stenosis on a per-patient basis: normal (no CAD), mild (1% to 39% of luminal stenosis),
llitus; FBS fasting blood sugar; HDL-C high-density lipoprotein cholesterol; LDL-C low-density
G Resultsummary XECG Results
No. of Patients According to XECG (%)*
Positive
(n  358)
Equivocal
(n  130)
Negative
(n  2,489)
256 (72%) 105 (81%) 2,207 (89%)
51 (14%) 19 (15%) 204 (8%)
25 (7%) 4 (3%) 63 (2%)
26 (7%) 2 (1%) 15 (1%)
134 (37%) 68 (52%) 1,466 (59%)
98 (27%) 32 (25%) 652 (26%)
70 (20%) 21 (16%) 281 (11%)
56 (16%) 9 (7%) 90 (4%)
ed according to most severely stenosed vessel (percentage of luminaled byAD
Mild
43
6
15
41
32
9
18
11
5
10
3
18
54
1
erity ofy XECto S
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estimatingMACE. In a univariate Cox regression analysis,
ositive XECG results, detailed XECG subsets including
xercise time (minutes), percentage of age-predicted heart
ate, exercise capacity (metabolic equivalent), and interme-
iate (10 to 4) and high (11) Duke treadmill scores
ere predictors of MACE (all p  0.05). Compared with
patients without CAD, those with obstructive CAD includ-
ing 1-VD, 2-VD, and 3-VD had significantly higher risk of
MACE (all p  0.001). For CAD severity model by
coronary CTA, we used a combined category of normal and
mild stenosis as a reference subset for Cox regression and
C-statistics analysis, because the MACE rate was extremely
low in patients in the normal category. Patients with
moderate and severe CAD experienced more MACE com-
pared with patients with normal and mild stenosis (all p 
0.001) (Table 4).
We also explored the prognostic value of coronary CTA
in relation to XECG. Patients with normal or mild stenosis
determined by coronary CTA had an excellent prognosis
independent of the XECG results. The Kaplan-Meier
5-year event rate of patients with negative XECG results
and normal or mild stenosis and patients with positive
XECG results and normal to mild CAD were 0.8% (95%
Major Adverse Cardiac Events According to Summary XECG and SeTable 3 Major Adverse Cardiac Events According to Summary
Variables n MACE*
5-Year C
Overall† 2,977 97 3
Summary XECG subset
Negative 2,489 54 2
Equivocal 130 3 2
Positive 358 40 12
Duke treadmill score (2,879) (95)
Low risk (5) 1,958 48 2
Intermediate risk (–10 to 4) 906 44 5
High risk (–11) 15 3 20
Coronary CTA: presence of
obstructive CAD (50%)
Absence of obstructive CAD 2,568 22 0
Presence of obstructive CAD 409 75 2
Coronary CTA: CAD extent‡
Absence of obstructive CAD 2,568 22 0
Obstructive 1-VD 274 39 15
Obstructive 2-VD 92 21 27
Obstructive 3-VD 43 15 32
Coronary CTA: CAD severity§
Normal (no CAD) 1,668 2 0
Mild stenosis (1%–39%) 782 15 2
Moderate stenosis (40%–69%) 372 36 12
Severe stenosis ( 70%) 155 44 28
*Number of patients with MACE or each subset of MACE. †Summary XECG and all coronary CTA m
available for only 2,879 patients, and 95 MACE were reported among them. ‡Number of obstru
arrowing in diameter stenosis).
CABG  coronary artery bypass graft; CD  cardiac death; MACE  major adverse cardiac even
revascularization including PCI and CABG after 90 days of index coronary CTA; UA  unstable angCI: 0.4 to 1.2) and 1.0% (95% CI: 0.2% to 3.6%), respec-tively. Compared with patients with negative XECG results
and normal to mild stenosis, patients with all other combi-
nations of XECG and coronary CTA models had a signif-
icantly increased risk of MACE (all p  0.001), except for
atients with positive XECG results and normal to mild
AD (p  0.616).
Multivariate XECG model and coronary CTA models
estimating MACE. In multivariate Cox regression analysis
adjusted by age, sex, hypertension, diabetes, current smok-
ing, and dyslipidemia, positive XECG results (HR: 4.53,
95% CI: 2.96 to 6.94, p  0.001) and detailed XECG
subsets, including exercise time (HR: 0.86, 95% CI: 0.77 to
0.95, p  0.003), percentage of age-predicted maximal
heart rate (HR: 0.98, 95% CI: 0.97 to 0.99, p 0.042), and
exercise capacity (HR: 0.85, 95% CI: 0.77 to 0.94, p 
.001) were associated with future MACE. In addition, the
ntermediate-risk group (HR: 1.72, 95% CI: 1.13 to 2.63,
 0.012) to high-risk group (HR: 10.51, 95% CI: 3.20 to
34.49, p  0.001), based on Duke treadmill score, had a
higher risk of MACE compared with the low-risk group.
By coronary CTA, as compared with patients without
CAD, the relative HR for MACE increased proportionally
to CAD extent for obstructive 1-VD (HR: 16.46, 95% CI:
9.30 to 29.12, p  0.001), 2-VD (HR: 24.52, 95% CI:
y of CAD by Coronary CTA Subsetand Severity of CAD by Coronary CTA Subset
tive Event Rate
% CI)
Subset of MACE*
CD NFMI UA
REV
PCI CABG
.0–4.3) 3 6 8 71 9
.8–3.1) 1 3 2 46 2
.6–7.2) 0 0 0 3 0
.3–16.5) 2 3 6 22 7
(3) (6) (8) (69) (9)
.1–3.6) 0 3 4 40 1
.0–7.0) 3 2 4 28 7
.3–48.6) 0 1 0 1 1
.6–1.4) 1 2 3 16 0
6.6–24.7) 2 4 5 55 9
.6–1.4) 1 2 3 16 0
1.7–20.6) 1 3 2 33 0
8.7–37.7) 0 1 2 15 3
9.8–49.0) 1 0 1 7 6
.03–0.5) 0 1 0 1 0
.3–3.5) 1 1 1 12 0
.0–15.9) 0 0 4 30 2
1.7–36.5) 2 4 3 28 7
re available for 2,977 patients, and 97 MACE were reported. However, Duke treadmill score was
50%) vessels. §Categorized according to most severely stenosed vessel (percentage of luminal
MI  nonfatal myocardial infarction; PCI  percutaneous coronary intervention; REV  coronary
her abbreviations as in Tables 1 and 2.veritXECG
umula
(95
.6% (3
.4% (1
.4% (0
.5% (9
.7% (2
.3% (4
.0% (5
.9% (0
0.4 (1
.9% (0
.6% (1
.3% (1
.9% (1
.1% (0
.1% (1
.1% (9
.6% (2
odels a
ctive (12.55 to 47.90, p  0.001), and 3-VD (HR: 38.20, 95%
X ith pos
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patients with normal to mild stenosis, those with moderate
stenosis (HR: 14.10, 95% CI: 7.41 to 26.84, p 0.001) and
severe stenosis (HR: 44.86, 95% CI: 23.79 to 84.60, p 
0.001) experienced proportionally an increased risk of
MACE (Table 4).
Compared with patients with negative XECG results and
normal or mild stenosis, patients with all other combina-
tions of XECG and coronary CTA models had a signifi-
cantly increased risk of MACE, with the exception of
patients with positive XECG results and normal to mild
CAD (HR: 1.51, 95% CI: 0.34 to 6.78, p  0.587). In
particular, subsets of patients exhibiting a high risk of
MACE (listed in increasing risk) included: 1) patients with
negative XECG results and moderate CAD (HR: 11.59,
95% CI: 5.33 to 24.27, p 0.001); 2) patients with positive
XECG results and moderate CAD (HR: 30.51, 95% CI:
Univariate and Multivariate Analysis for Prediction of Major AdversTable 4 Univariate and Multivariate Analysis for Prediction of M
Variable HR
Summary XECG subset
Negative 1.00
Positive 5.56
Detailed XECG subset
Exercise time (min) 0.82
% Predicted heart rate 0.98
Exercise capacity (1-MET) 0.82
Maximum BP (systolic) 1.01
Duke treadmill score
Low risk (5) 1.00
Intermediate risk (–10 to 4) 2.08
High risk (–11) 10.94
Presence of obstructive CAD
No obstructive CAD 1.00
Presence of obstructive CAD 25.97
Extent of CAD
No obstructive CAD 1.00
Obstructive 1-VD 19.88
Obstructive 2-VD 32.28
Obstructive 3-VD 52.34
Severity of CAD
Normal to mild (40%) 1.00
Moderate (40%–69%) 16.77
Severe (70%) 54.91
Combined model of coronary CTA (severity of CAD) and XECG
XECGnegCTno/mild 1.00
XECGnegCTmod 13.33
XECGnegCTsev 37.12
XECGposCTno/mild 1.46
XECGposCTmod 34.07
XECGposCTsev 92.97
*Adjustment for clinical risk factors including age, sex, hypertension, diabetes mellitus, and dysli
BP blood pressure; CI confidence interval; HR hazard ratio; METmetabolic equivalents; X
with negative XECG results and moderate CAD; XECGnegCTsev  patients with negative XECG res
ECGposCTmod patients with positive XECG results and moderate CAD; XECGposCTsev patients w
heart rate. Other abbreviations as in Tables 1 and 2.13.67 to 68.08, p  0.001); 3) patients with negativeXECG results and severe CAD (HR: 32.44, 95% CI: 15.28
to 68.89, p  0.001); and 4) patients with positive XECG
results and severe CAD (HR: 79.33, 95% CI: 37.28 to
168.82, p  0.001). Risk-adjusted overall MACE-free
survival according to XECG subset (positive vs. negative
results), coronary CTA models, including extent and sever-
ity of CAD, and combined models of XECG and coronary
CTA are plotted in Figure 1.
Discriminatory function of future MACE. As described
in Table 5, compared with clinical RF alone (C-statistics:
0.746, 95% CI: 0.695 to 0.796), summary XECG (C-
statistics: 0.790, 95% CI: 0.742 to 0.839), summary XECG
plus Duke treadmill score (C-statistics: 0.789, 95% CI:
0.741 to 0.838), and severity of CAD on coronary CTA
(C-statistics: 0.909, 95% CI: 0.883 to 0.936) had an added
benefit for prediction of future MACE (all p  0.001 for
differences). Compared with the summary XECG model
diac EventsAdverse Cardiac Events
iate Analysis Multivariate Analysis*
5% CI p Value HR 95% CI p Value
1.00
7–8.43 0.001 4.53 2.96–6.94 0.001
5–0.89 0.001 0.86 0.77–0.95 0.003
6–0.99 0.013 0.98 0.97–0.99 0.042
5–0.89 0.001 0.85 0.77–0.94 0.001
0–1.02 0.135 1.00 0.99–1.01 0.977
1.00
7–3.15 0.001 1.72 1.13–2.63 0.012
0–35.18 0.001 10.51 3.20–34.49 0.001
1.00
4–42.58 0.001 20.14 11.81–34.35 0.001
0.001† 0.001†
1.00
9–34.10 0.001 16.46 9.30–29.12 0.001
9–59.56 0.001 24.52 12.55–47.90 0.001
2–103.70 0.001 38.20 18.37–79.44 0.001
0.001† 0.001†
1.00
8–30.64 0.001 14.10 7.41–26.84 0.001
9–98.90 0.001 44.86 23.79–84.60 0.001
1.00
2–26.03 0.001 11.59 5.33–24.27 0.001
8–75.78 0.001 32.44 15.28–68.89 0.001
3–6.49 0.616 1.51 0.34–6.78 0.587
1–72.51 0.001 30.51 13.67–68.08 0.001
1–183.88 0.001 79.33 37.28–168.82 0.001
. †p Value for trend.
CTno/mild patients with negative XECG results and normal tomild CAD; XECGnegCTmod patients
d severe CAD; XECGposCTno/mild  patients with positive XECG results and normal to mild CAD;
itive XECG results and severe CAD; %predicted heart rate percentage of age predicted maximale Carajor
Univar
9
3.6
0.7
0.9
0.7
1.0
1.3
3.4
15.8
11.5
17.4
26.4
9.1
30.4
6.5
18.1
0.3
16.0
47.0
pidemia
ECGneg
ults an(model 2), an addition of Duke treadmill score did not show
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contrast, the addition of coronary CTA findings to the
summary XECG model (model 5, C-statistics: 0.908, 95%
CI: 0.890 to 0.937) and the summary XECG results plus
Duke treadmill score (model 6, C-statistics: 0.909, 95% CI:
0.880 to 0.938) showed significant increment in C-statistics
compared with their baseline models without coronary
Figure 1 Major Adverse Cardiac Event-Free Survival Stratified b
the Severity and Extent of Coronary Artery Disease Ev
Risk-adjusted major adverse cardiac event (MACE)-free survival (A) by summary ex
computed tomographic angiography (CTA)-diagnosed coronary artery disease (CAD)
model of summary XECG and severity of CAD by coronary CTA. Risk adjustment in
ing, and dyslipidemia. mod  moderate; neg  negative; pos  positive; sev  sCTA findings (models 2 and 3, respectively, all p  0.001for difference). Compared with the baseline coronary CTA
model (model 4), however, an addition of summary XECG
results (model 5) or summary XECG plus Duke treadmill
score (model 6) failed to discriminate future risk of MACE
(p  0.638 and p  0.545 for difference, respectively).
The discriminatory function of other coronary CTA
models, including the binary CAD model (presence or
mmary Exercise Electrocardiography Subset and
ced by Coronary Computed Tomography Angiography
electrocardiography (XECG) subset (positive vs. negative results), by coronary
fied by (B) extent of disease and (C) severity of disease, and (D) by combined
the following variables: age, sex, hypertension, diabetes mellitus, current smok-
VD  vessel disease.y Su
iden
ercise
strati
cluded
evere;absence of obstructive CAD) and extent of CAD (number
al or m
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Tables 4 and 5). The C-statistics of binary CAD model
(0.885, 95% CI: 0.851 to 0.920) and extent of CAD
(C-statistics: 0.888, 95% CI: 0.853 to 0.922) were slightly
lower than those of the severity of CAD model, but
discriminatory function compared with clinical RF and
XECG results was similar.
Patient subset analyses. To determine predicted power of
coronary CTA in relation to XECG, we also examined the
predictive value of coronary CTA in a subgroup categorized
by XECG and the predictive value of XECG in a subgroup
categorized by severity of CAD determined by coronary
CTA (Fig. 2). Severity of CAD determined by coronary
CTA successfully stratified future risk of MACE in the
group with positive XECG results as well as the group with
negative XECG results (all p  0.001 for trend).
However, XECG failed to stratify future risk of
MACE in the group with normal to mild stenosis on
coronary CTA (compared with negative XECG results,
HR: 1.28, 95% CI: 0.28 to 5.82, p  0.746). Abnormal-
ity of XECG results predicted future risk of MACE only
in the subgroups of patients with moderate stenosis
(compared with negative XECG results, HR: 2.58, 95%
CI: 1.29 to 5.19, p  0.008) and severe stenosis (com-
pared with negative XECG results, HR: 2.28, 95% CI:
1.19 to 4.38, p  0.013).
Discussion
Our study aimed to investigate the roles of coronary CTA
and XECG in the risk stratification of patients undergoing
initial evaluation with suspected CAD. The main finding of
this study is that, in a large number of patients with
suspected CAD, both XECG and coronary CTA are
independently predictive of MACE, but there is no overall
incremental benefit for predicting future MACE when
XECG is added to coronary CTA. In subgroup analyses,
coronary CTA stratifies risk of future MACE in both
XECG-negative and XECG-positive groups. However,
XECG stratifies future risk of MACE only in coronary
C-Statistics for Prediction of 5-Year Risk of Major Adverse CardiacUsing XECG, Coronary CTA (Sev rity of CAD), and Combined ModeTable 5 C-Statistics for Pr dic ion of 5-Ye r Risk of Major A veUsing XECG, Coronary CTA (Severity of CAD), and Com
Model C-Statistics
Model 1: clinical risk factors* 0.746 (0.695–0.796)
Model 2: model 1  summary XECG‡ 0.790 (0.742–0.839)
Model 3: model 2  Duke treadmill score 0.789 (0.741–0.838)
Model 4: model 1  coronary CTA§ 0.909 (0.883–0.936)
Model 5: model 2  coronary CTA§ 0.908 (0.890–0.937)
Model 6: model 3  coronary CTA§ 0.909 (0.880–0.938)
*Only the comparisons between baseline models and their nested models were presented. †Clin
‡Summary XECG model: positive vs. negative. §Severity of CAD diagnosed by coronary CTA: norm
NA  not applicable; other abbreviations as in Tables 1, 2, 3, and 4.CTA subgroups of moderate or severe stenoses.XECG as an initial evaluation of patients with suspected
CAD. Because of its widespread availability, lower cost, and
simplicity of its operation and interpretation, XECG has been
recommended as the initial diagnostic test for suspected CAD
patients with a normal resting ECG results who are able to
exercise (14). However, considerable evidence exists that dem-
onstrates the limitations of XECG as a diagnostic method
because of its relatively low sensitivity and specificity (20,21).
Furthermore, it has been reported that there are some limita-
tions regarding the use of XECG to identify high-risk patients
in the evaluation of suspected CAD (22).
Prognostic value of coronary CTA. Coronary CTA has
emerged as a novel diagnostic tool with high sensitivity and
specificity that demonstrated superiority to XECG in de-
tecting CAD in previous head-to-head comparisons (23).
In recent 64-slice multidetector coronary CTA studies, the
negative predictive value reached 99%, which is higher than
that of any other noninvasive imaging techniques (24).
Accordingly, it has been suggested that coronary CTA
could be used as a first-line imaging technique to exclude
CAD and to replace invasive coronary angiography in some
patients (25). Prognosis prediction of patients suspected of
having CAD is as important as detecting disease, because it
determines the subsequent treatment plan. Recent studies
have shown the potential prognostic value of coronary CTA
in suspected CAD patients (26,27). However, to date, it
remains unclear whether coronary CTA adds prognostic
usefulness beyond standard exercise test findings in patients
who are classified according to XECG results, as well as
whether XECG adds incremental prognostic value to cor-
onary CTA.
Prognostic value of coronary CTA in relation to XECG.
To our knowledge, this is the first registry analysis to
suggest that coronary CTA interpretations of CAD im-
prove classification above and beyond XECG findings in a
large cohort with suspected CAD. The current study demon-
strated an incremental prognostic value of coronary CTA on
XECG findings in the overall population (Table 5). In
subgroup analyses, coronary CTA stratifies future risk of
MACE in groups with both negative and positive XECG
tardiac Event
d Model
p Value for Difference* of C-Statistics Compared With Models
Model 1 Model 2 Model 3 Model 4
NA NA NA NA
0.015 NA NA NA
0.020 0.707 NA NA
0.001 NA NA NA
0.001 0.001 NA 0.638
0.001 NA 0.001 0.545
k factors included age, sex, hypertension, dyslipidemia, diabetes mellitus, and current smoking.
ild (40%), moderate (40%–69%), and severe CAD (70%).Evenlrs C
bine
ical risresults (Figs. 2A and 2B). Therefore, coronary CTA could
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both negative and positive XECG results. In contrast, the
added prognostic benefit of XECG to coronary CTA
models is not observed in the overall population (Table 5).
In subgroup analyses, positive XECG findings are associ-
ated significantly with future risk of MACE in patients with
moderate to severe stenosis (Figs. 2D and 2E), but not in
patients with normal to mild stenosis (Fig. 2C). Thus,
XECG can be of value only in patients with moderate to
severe stenosis on coronary CTA. The clinical implications
Figure 2 MACE-Free Survival in Each Subset of XECG and Coro
Risk-adjusted MACE-free survival of patients according to coronary artery disease s
XECG. Risk-adjusted MACE-free survival of patients according to summary XECG su
severe stenosis detected by coronary CTA. CI  confidence interval; HR  hazardof the current study are summarized in Online Table 6.Furthermore, the current study also generated the hy-
pothesis that coronary CTA may be used as a first-line test
in patients with suspected CAD in lieu of XECG. There
was a proportional increase in future risk of MACE accord-
ing to the extent and severity of CAD detected by coronary
CTA. In particular, coronary CTA demonstrated its clinical
usefulness by identifying patients without significant steno-
sis who had an excellent prognosis: the 5-year cumulative
event rate of patients with normal to mild stenosis on
coronary CTA was less than 1.0%. Therefore, we can
CTA
y detected by coronary CTA in subgroup of (A) negative XECG and (B) positive
n a subgroup of (C) normal to mild stenosis, (D) moderate stenosis, and (E)
other abbreviations as in Figure 1.nary
everit
bset i
ratio;identify patients with excellent prognosis accurately by
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avoided in this population. In our present cohort, among
2,977 symptomatic patients, coronary CTA identified 2,568
(86%) patients without obstructive CAD (50%) and 2,450
(82%) patients without moderate to severe stenosis (40%)
to be at low risk (Table 3). On the contrary, a non-
negligible proportion of patients with negative XECG
results are found to have moderate to severe stenosis on
coronary CTA (15%) and to experience higher 5-year
cumulative event rates of 2.4% (95% CI, 1.8% to 3.1%)
compared with those patients without obstructive CAD on
coronary CTA. These findings emphasize an important
limitation of nonimaging exercise-induced ST-segment de-
pression for risk stratification, as has been reported in prior
studies (28).
However, despite the powerful prognostic value, coronary
CTA has potential limitations, including radiation hazard,
use of iodinated contrast agents, and higher cost compared
with that of XECG. In addition, most cardiac events in the
current study were revascularization procedures, so the
prognostic value of coronary CTA to predict a so-called
hard event was not evaluated fully. Moreover, the cumula-
tive events rate of 2.4% in patients with negative XECG
results is a fairly good prognosis, although it is higher than
the cumulative events rate in patients without obstructive
CAD detected by coronary CTA. Therefore, the decision to
use coronary CTA as a first-line diagnostic method in
patients with suspected CAD should be deferred until the
potential risk-to-benefit ratio, cost effectiveness, and clinical
efficiency are weighed by prospective randomized trials.
Further, future comprehensive studies also are warranted to
determine the most cost-effective, safe, and clinically effi-
cient strategy to diagnose CAD and to predict future risk of
cardiac events in low- to intermediate-risk symptomatic
patients without known CAD covering various diagnostic
methods, such as coronary CTA, XECG, myocardial per-
fusion imaging, and stress echocardiography.
Study limitations. The present study was retrospective and
may have been influenced by unobserved confounders and
selection or referral biases, or both. In addition, the effect of
post-test medical treatments or risk factor control was not
considered. Especially given the potential advantage of
coronary CTA to identify nonobstructive CAD for predic-
tion of future cardiac events (29), further studies are
warranted to assess the impact of medical therapies in
patients with nonobstructive CAD on coronary CTA.
Although we considered only revascularizations more
than 90 days after coronary CTA as outcome events,
revascularizations from the index test may have been in-
cluded. Moreover, the pretest probability of the study
population was relatively low, which limits the number of
clinical events at follow-up. However, to our knowledge, the
population size of this study is the largest to date reporting
concurrent XECG and coronary CTA findings in relation
to downstream clinical outcomes, and we plan to continueto follow through with our investigation to understand the
long-term nature of these study findings.
Conclusions
In patients with suspected but without known CAD,
coronary CTA demonstrates added prognostic benefit in
patients with both positive and negative XECG results. In
particular, the clinical usefulness of coronary CTA is real-
ized by identifying patients with normal or mild stenosis
(40%) and accurately predicting the very low risk of future
cardiac events. Conversely, XECG has additive value for
risk stratification on coronary CTA only in patients with
moderate to severe stenosis.
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